Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients with CLL

Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients with CLL. Blood. 2006; 108(11):804a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.